MCUJF MEDICURE INC IFRS
Pharmaceutical Preparations · OTC · SEC CIK 1133519 · Reporting currency CAD · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY1.0%
TTM net income YoY-12.7%
TTM EPS YoY-11.1%
Revenue 3-yr CAGR0.2%
Net income 3-yr CAGR—
Margins
Gross margin59.7%
Operating margin—
Net margin-4.7%
FCF margin—
EBITDA margin—
Returns
ROE-5.1%
ROA-3.6%
ROIC (approx.)—
Asset turnover0.76x
Leverage & solvency
Liabilities / assets30.0%
Debt / equity0.00x
Current ratio1.89x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.33x
Accruals ratio-8.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2024*2024-12-31 | FY2023*2023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 21.91M | 21.69M |
| Cost of revenue | 8.82M | 7.71M |
| Gross profit | 13.09M | 13.99M |
| R&D expense | 3.08M | 2.41M |
| SG&A expense | 4.76M | 4.13M |
| Pretax income | -783,000 | -897,000 |
| Income tax | -256,000 | -25,000 |
| Net income | -1.04M | -922,000 |
| EPS (basic) | -0.10 | -0.09 |
| EPS (diluted) | -0.10 | -0.09 |
| Weighted avg. shares (diluted) | 10.44M | 10.44M |
| Balance sheet | ||
| Cash & equivalents | 7.19M | 6.37M |
| Receivables | 5.30M | 4.79M |
| Inventory | 3.28M | 2.90M |
| Current assets | 15.90M | 15.21M |
| PP&E, netmay include right-of-use assets (IFRS) | 955,000 | 736,000 |
| Goodwill | 3.38M | 3.10M |
| Intangibles | 9.35M | 8.94M |
| Total assets | 29.68M | 28.06M |
| Current liabilities | 8.39M | 7.93M |
| Total liabilities | 8.90M | 8.16M |
| Shareholders' equity | 20.78M | 19.90M |
| Cash flow statement | ||
| Operating cash flow | 1.38M | 2.08M |
| Investing cash flow | -739,000 | -270,000 |
| Financing cash flow | -370,000 | -297,000 |
| Stock-based compensation | 196,000 | 288,000 |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.